中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.021 seconds)

    COMPOSITIONS AND METHODS OF TREATING CANCER
    1.
    发明专利
    COMPOSITIONS AND METHODS OF TREATING CANCER 未知

    公开(公告)号：CA2691510A1

    公开(公告)日：2008-12-31

    申请号：CA2691510

    申请日：2008-06-26

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： TOGASHI AKIRA ,  TOBITA RYUTARO ,  ISHIZAKI YUKA ,  KONUMA AKIKO

    IPC: C12N15/00 ,  A61K31/7105 ,  A61K48/00 ,  A61P35/00

    Abstract: The invention features a method for treating cancer by administering a do uble-stranded nucleic acid molecule against a CX gene selected from the grou p consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also feature s products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder canc er, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testi cular seminoma.

    TBC1D7 AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER
    3.
    发明专利
    TBC1D7 AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER 未知

    公开(公告)号：CA2735182A1

    公开(公告)日：2010-03-04

    申请号：CA2735182

    申请日：2009-08-14

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  TOGASHI AKIRA

    IPC: C12Q1/68 ,  A61K48/00 ,  A61P35/00 ,  C07K7/04 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/574

    Abstract: The present invention relates to the roles played by the TBC1D7 genes in cancer, in particular, lung cancer or esophageal cancer, or carcinogenesis and features a method for treating and/or preventing cancer, in particular, lung cancer or esophageal cancer by administering a double-stranded molecule against one or more of the TBC1D7 genes or a composition, vector or cell containing such a double stranded molecule. The present invention also features methods for diagnosing lung or assessing/determining the prognosis of a patient with lung, especially NSCLC or SCLC, or esophageal cancer, using one or more over-expressed genes selected from among TBC1D7. To that end, TBC1D7 may serve as a novel biomarker for lung cancer or esophageal cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung or esophageal cancer, using as an index for their effect on the over-expression of one or more of TBC1D7 in the lung cancer or esophageal cancer.

    C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    4.
    发明专利
    C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 未知

    公开(公告)号：CA2735145A1

    公开(公告)日：2010-03-04

    申请号：CA2735145

    申请日：2009-08-21

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  NAKAGAWA HIDEWAKI ,  TOGASHI AKIRA

    IPC: C12N15/09

    Abstract: Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them.

    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    7.
    发明专利
    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 未知

    公开(公告)号：CA2735148A1

    公开(公告)日：2010-03-04

    申请号：CA2735148

    申请日：2009-08-24

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  TOGASHI AKIRA

    IPC: C12N15/09 ,  C12Q1/68

    Abstract: The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody.The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5.

    SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    8.
    发明专利
    SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 未知

    公开(公告)号：CA2734979A1

    公开(公告)日：2010-03-04

    申请号：CA2734979

    申请日：2009-08-24

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  TOGASHI AKIRA

    IPC: C12N15/09 ,  A61K31/713 ,  A61K48/00 ,  A61P35/00 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53

    Abstract: The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.

    Anticuerpos anti-CDH3 marcados con etiqueta de radioisótopo y usos de los mismos
    10.
    发明专利
    Anticuerpos anti-CDH3 marcados con etiqueta de radioisótopo y usos de los mismos 未知

    公开(公告)号：ES2534437T3

    公开(公告)日：2015-04-22

    申请号：ES09773163

    申请日：2009-06-30

    Applicant: ONCOTHERAPY SCIENCE INC

    Inventor： TOGASHI AKIRA ,  KATSU MASAKAZU ,  TAKAYANAGI MEGUMI ,  YOSHIOKA HIROKI ,  NG POHSING ,  SHIBA YASUHIRO ,  NAKAMURA YUSUKE ,  ENDO KEIGO

    IPC: A61K39/00 ,  A61K51/10 ,  C07K16/28 ,  G01N33/574

    Abstract: Un anticuerpo o un fragmento del mismo, que reconoce específicamente un polipéptido que tiene la secuencia de aminoácidos como se muestra en SEQ ID NO: 3, en el que el anticuerpo o fragmento del mismo es (i) un anticuerpo que comprende regiones variables definidas por las secuencias de aminoácidos de SEQ ID NO: 11 y 12, o un fragmento de unión del anticuerpo, en el que dicho fragmento de unión comprende regiones variables definidas por las secuencias de aminoácidos de SEQ ID NO: 11 y 12; o (ii) un anticuerpo definido por CDR de VH que tienen las secuencias de aminoácidos de SEQ ID NO: 13, 14 y 15 y CDR de VL que tienen las secuencias de aminoácidos de SEQ ID NO: 16, 17 y 18, o un fragmento de unión del anticuerpo, en el que dicho fragmento de unión comprende CDR de VH que tienen las secuencias de aminoácidos de SEQ ID NO: 13, 14 y 15 y CDR de VL que tienen las secuencias de aminoácidos de SEQ ID NO: 16, 17 y 18.

Patent Agency Ranking